Opinion | ‘This Error Left People in Terrible Financial Situations’: What We Heard This Week

“This error left people in terrible financial situations.” — David Dent, PharmD, first-year pharmacy resident, discussing a National Association of Boards of Pharmacy error that led more than 200 recent pharmacy graduates to believe they failed the national pharmacy board exam when they actually had passed.

“Standard Time is ‘the biologically correct time.'” — Anna Yap, MD, speaking on behalf of the Resident and Fellow Section of the American Medical Association about eliminating Daylight Saving Time.

“It’s not as simple as saying, ‘Oh, you shouldn’t go to the ER because we’re busy, or the ER saying you should go to primary care because we’re busy. Everybody is busy.” — Katie Lockwood, MD, MEd, of Children’s Hospital of Philadelphia, noting that patient volume is high everywhere now.

“Usually, more choice is better.” — C. Noel Bairey Merz, MD, of Cedars-Sinai Medical Center in Los Angeles, who recommended approval of tenapanor (Ibsrela) for chronic kidney disease patients on dialysis at an FDA advisory committee meeting.

“The groundwork was laid before this. The pandemic simply pushed that trend into high gear.” — Eugene Declercq, PhD, of Boston University, on the continuing upward trend of home births in the U.S.

“To potentially have a therapy that doesn’t require a needle is very exciting.” — Brian Kelly, MD, of Midwest Allergy and Asthma Center in Omaha, discussing a sublingual film that may be able to deliver epinephrine as effectively as intramuscular injections.

“We as providers are in a position to provide care that is gender-affirming in the inpatient setting, by using their correct names, pronouns, and linking them to evidence-based, gender-affirming medical and mental health care in the outpatient setting. Their lives depend on it.” — Nadir Yehya, MD, of Children’s Hospital of Philadelphia, on the rates of hospitalizations due to suicidality and self-harm in young people with gender dysphoria.

“In a sense, this is a transplant unmatched therapy, so it is very exciting that this has really worked so well.” — Pamela Ohashi, PhD, of Princess Margaret Cancer Centre in Toronto, regarding the investigational allogeneic CAR T-cell therapy CTX130 for patients with advanced clear cell renal cell carcinoma.